PDL BioPharma Inc - Strategic SWOT Analysis Review

April 2021 | 45 pages | ID: P9715C3AB24FEN
GlobalData

Abstracts

PDL BioPharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to public and private healthcare companies. PDL provides companies, academic institutions and inventors with an immediate financial monetization of royalty streams for acquiring new income-generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc Key Recent Developments

Dec 08,2020: PDL announces timeline for voluntarily delisting from Nasdaq
Nov 11,2020: PDL BioPharma reports 2020 third quarter financial results and sets date to file a certificate of dissolution
Nov 06,2020: PDL BioPharma reschedules third quarter 2020 financial results and business update
Aug 15,2020: PDL BioPharma announces departure of certain officers
Aug 12,2020: PDL BioPharma enters into settlement agreement with Wellstat

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

PDL BioPharma Inc - Key Facts
PDL BioPharma Inc - Key Employees
PDL BioPharma Inc - Key Employee Biographies
PDL BioPharma Inc - Major Products and Services
PDL BioPharma Inc - History
PDL BioPharma Inc - Company Statement
PDL BioPharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
PDL BioPharma Inc - Business Description
Business Segment: Income Generating Assets
Overview
Performance
Business Segment: Medical Devices
Overview
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
PDL BioPharma Inc - Corporate Strategy
PDL BioPharma Inc - SWOT Analysis
SWOT Analysis - Overview
PDL BioPharma Inc - Strengths
PDL BioPharma Inc - Weaknesses
PDL BioPharma Inc - Opportunities
PDL BioPharma Inc - Threats
PDL BioPharma Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
PDL BioPharma Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Dec 08, 2020: PDL announces timeline for voluntarily delisting from Nasdaq
Nov 11, 2020: PDL BioPharma reports 2020 third quarter financial results and sets date to file a certificate of dissolution
Nov 06, 2020: PDL BioPharma reschedules third quarter 2020 financial results and business update
Aug 15, 2020: PDL BioPharma announces departure of certain officers
Aug 12, 2020: PDL BioPharma enters into settlement agreement with Wellstat
Aug 06, 2020: PDL BioPharma reports 2020 second quarter financial results
May 07, 2020: PDL BioPharma reports 2020 first quarter financial results
Mar 11, 2020: PDL BioPharma reports 2019 fourth quarter and full year financial results and announces plan to dissolve the company by year-end 2020
Mar 09, 2020: PDL BioPharma announces appointment of Edward A. Imbrogno as vice president and chief financial officer
Feb 28, 2020: PDL BioPharma Enters into cooperation agreement with Engine Capital

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

PDL BioPharma Inc, Key Facts
PDL BioPharma Inc, Key Employees
PDL BioPharma Inc, Key Employee Biographies
PDL BioPharma Inc, History
PDL BioPharma Inc, Subsidiaries
PDL BioPharma Inc, Key Competitors
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
PDL BioPharma Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021